Global Peripherally Acting Anti-Obesity Drug 麻豆原创 Growth 2024-2030

Publication ID:

LPI08246080

Publication Date:

August 21, 2024

Pages:

120

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

A Peripherally Acting Anti-Obesity Drug is a medication designed to treat obesity by acting on the peripheral nervous system or other systems in the body. These drugs target various mechanisms involved in appetite regulation, metabolism, and fat absorption to aid in weight loss.
The global Peripherally Acting Anti-Obesity Drug market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The 鈥淧eripherally Acting Anti-Obesity Drug Industry Forecast鈥� looks at past sales and reviews total world Peripherally Acting Anti-Obesity Drug sales in 2023, providing a comprehensive analysis by region and market sector of projected Peripherally Acting Anti-Obesity Drug sales for 2024 through 2030. With Peripherally Acting Anti-Obesity Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peripherally Acting Anti-Obesity Drug industry.
This Insight Report provides a comprehensive analysis of the global Peripherally Acting Anti-Obesity Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peripherally Acting Anti-Obesity Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Peripherally Acting Anti-Obesity Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peripherally Acting Anti-Obesity Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peripherally Acting Anti-Obesity Drug.
United States market for Peripherally Acting Anti-Obesity Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Peripherally Acting Anti-Obesity Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Peripherally Acting Anti-Obesity Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Peripherally Acting Anti-Obesity Drug players cover Novo Nordisk A/S, Pfizer Inc., Boehringer Ingelheim International GmbH, KVK Tech Inc. and Gelesis Holdings, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Peripherally Acting Anti-Obesity Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Prescription Drugs
Non-prescription Drugs
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk A/S
Pfizer Inc.
Boehringer Ingelheim International GmbH
KVK Tech Inc.
Gelesis Holdings
Vivus LLC.
Currax Pharmaceuticals LLC
GlaxoSmithKline plc
CHEPLAPHARM Arzneimittel GmbH
Rhythm Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Peripherally Acting Anti-Obesity Drug market?
What factors are driving Peripherally Acting Anti-Obesity Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Peripherally Acting Anti-Obesity Drug market opportunities vary by end market size?
How does Peripherally Acting Anti-Obesity Drug break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Peripherally Acting Anti-Obesity Drug by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Peripherally Acting Anti-Obesity Drug by Country/Region, 2019, 2023 & 2030
2.2 Peripherally Acting Anti-Obesity Drug Segment by Type
2.2.1 Prescription Drugs
2.2.2 Non-prescription Drugs
2.3 Peripherally Acting Anti-Obesity Drug Sales by Type
2.3.1 Global Peripherally Acting Anti-Obesity Drug Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Peripherally Acting Anti-Obesity Drug Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Peripherally Acting Anti-Obesity Drug Sale Price by Type (2019-2024)
2.4 Peripherally Acting Anti-Obesity Drug Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Peripherally Acting Anti-Obesity Drug Sales by Application
2.5.1 Global Peripherally Acting Anti-Obesity Drug Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Peripherally Acting Anti-Obesity Drug Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Peripherally Acting Anti-Obesity Drug Sale Price by Application (2019-2024)
3 Global Peripherally Acting Anti-Obesity Drug by Company
3.1 Global Peripherally Acting Anti-Obesity Drug Breakdown Data by Company
3.1.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales by Company (2019-2024)
3.1.2 Global Peripherally Acting Anti-Obesity Drug Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue by Company (2019-2024)
3.2.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Company (2019-2024)
3.2.2 Global Peripherally Acting Anti-Obesity Drug Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Peripherally Acting Anti-Obesity Drug Sale Price by Company
3.4 Key Manufacturers Peripherally Acting Anti-Obesity Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peripherally Acting Anti-Obesity Drug Product Location Distribution
3.4.2 Players Peripherally Acting Anti-Obesity Drug Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Peripherally Acting Anti-Obesity Drug by Geographic Region
4.1 World Historic Peripherally Acting Anti-Obesity Drug 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Peripherally Acting Anti-Obesity Drug 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales by Country/Region (2019-2024)
4.2.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue by Country/Region (2019-2024)
4.3 Americas Peripherally Acting Anti-Obesity Drug Sales Growth
4.4 APAC Peripherally Acting Anti-Obesity Drug Sales Growth
4.5 Europe Peripherally Acting Anti-Obesity Drug Sales Growth
4.6 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Growth
5 Americas
5.1 Americas Peripherally Acting Anti-Obesity Drug Sales by Country
5.1.1 Americas Peripherally Acting Anti-Obesity Drug Sales by Country (2019-2024)
5.1.2 Americas Peripherally Acting Anti-Obesity Drug Revenue by Country (2019-2024)
5.2 Americas Peripherally Acting Anti-Obesity Drug Sales by Type
5.3 Americas Peripherally Acting Anti-Obesity Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peripherally Acting Anti-Obesity Drug Sales by Region
6.1.1 APAC Peripherally Acting Anti-Obesity Drug Sales by Region (2019-2024)
6.1.2 APAC Peripherally Acting Anti-Obesity Drug Revenue by Region (2019-2024)
6.2 APAC Peripherally Acting Anti-Obesity Drug Sales by Type
6.3 APAC Peripherally Acting Anti-Obesity Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Peripherally Acting Anti-Obesity Drug by Country
7.1.1 Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2019-2024)
7.1.2 Europe Peripherally Acting Anti-Obesity Drug Revenue by Country (2019-2024)
7.2 Europe Peripherally Acting Anti-Obesity Drug Sales by Type
7.3 Europe Peripherally Acting Anti-Obesity Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug by Country
8.1.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2019-2024)
8.1.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue by Country (2019-2024)
8.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Type
8.3 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peripherally Acting Anti-Obesity Drug
10.3 Manufacturing Process Analysis of Peripherally Acting Anti-Obesity Drug
10.4 Industry Chain Structure of Peripherally Acting Anti-Obesity Drug
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peripherally Acting Anti-Obesity Drug Distributors
11.3 Peripherally Acting Anti-Obesity Drug Customer
12 World Forecast Review for Peripherally Acting Anti-Obesity Drug by Geographic Region
12.1 Global Peripherally Acting Anti-Obesity Drug 麻豆原创 Size Forecast by Region
12.1.1 Global Peripherally Acting Anti-Obesity Drug Forecast by Region (2025-2030)
12.1.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Peripherally Acting Anti-Obesity Drug Forecast by Type
12.7 Global Peripherally Acting Anti-Obesity Drug Forecast by Application
13 Key Players Analysis
13.1 Novo Nordisk A/S
13.1.1 Novo Nordisk A/S Company Information
13.1.2 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novo Nordisk A/S Main Business Overview
13.1.5 Novo Nordisk A/S Latest Developments
13.2 Pfizer Inc.
13.2.1 Pfizer Inc. Company Information
13.2.2 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Pfizer Inc. Main Business Overview
13.2.5 Pfizer Inc. Latest Developments
13.3 Boehringer Ingelheim International GmbH
13.3.1 Boehringer Ingelheim International GmbH Company Information
13.3.2 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.3.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Boehringer Ingelheim International GmbH Main Business Overview
13.3.5 Boehringer Ingelheim International GmbH Latest Developments
13.4 KVK Tech Inc.
13.4.1 KVK Tech Inc. Company Information
13.4.2 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.4.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 KVK Tech Inc. Main Business Overview
13.4.5 KVK Tech Inc. Latest Developments
13.5 Gelesis Holdings
13.5.1 Gelesis Holdings Company Information
13.5.2 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.5.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Gelesis Holdings Main Business Overview
13.5.5 Gelesis Holdings Latest Developments
13.6 Vivus LLC.
13.6.1 Vivus LLC. Company Information
13.6.2 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.6.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Vivus LLC. Main Business Overview
13.6.5 Vivus LLC. Latest Developments
13.7 Currax Pharmaceuticals LLC
13.7.1 Currax Pharmaceuticals LLC Company Information
13.7.2 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.7.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Currax Pharmaceuticals LLC Main Business Overview
13.7.5 Currax Pharmaceuticals LLC Latest Developments
13.8 GlaxoSmithKline plc
13.8.1 GlaxoSmithKline plc Company Information
13.8.2 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.8.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 GlaxoSmithKline plc Main Business Overview
13.8.5 GlaxoSmithKline plc Latest Developments
13.9 CHEPLAPHARM Arzneimittel GmbH
13.9.1 CHEPLAPHARM Arzneimittel GmbH Company Information
13.9.2 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 CHEPLAPHARM Arzneimittel GmbH Main Business Overview
13.9.5 CHEPLAPHARM Arzneimittel GmbH Latest Developments
13.10 Rhythm Pharmaceuticals
13.10.1 Rhythm Pharmaceuticals Company Information
13.10.2 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.10.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Rhythm Pharmaceuticals Main Business Overview
13.10.5 Rhythm Pharmaceuticals Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.